2552-54-7 | Heterocyclic Building Blocks-isoxazole

S-21 News Simple exploration of 2552-54-7

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 2552-54-7, and how the biochemistry of the body works.Application of 2552-54-7

Application of 2552-54-7, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.2552-54-7, Name is 3-(Benzyloxy)isoxazole-5-carboxylic acid, molecular formula is C11H9NO4. In a Patent，once mentioned of 2552-54-7

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Top Picks: new discover of 3-(Benzyloxy)isoxazole-5-carboxylic acid

Reference of 2552-54-7, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 2552-54-7, Name is 3-(Benzyloxy)isoxazole-5-carboxylic acid,introducing its new discovery.

The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

More research is needed about 2552-54-7

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, name: 3-(Benzyloxy)isoxazole-5-carboxylic acid, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 2552-54-7

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, name: 3-(Benzyloxy)isoxazole-5-carboxylic acid, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 2552-54-7, Name is 3-(Benzyloxy)isoxazole-5-carboxylic acid, molecular formula is C11H9NO4

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The important role of 2552-54-7

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Safety of 3-(Benzyloxy)isoxazole-5-carboxylic acid, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 2552-54-7, in my other articles.

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Safety of 3-(Benzyloxy)isoxazole-5-carboxylic acid, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 2552-54-7, Name is 3-(Benzyloxy)isoxazole-5-carboxylic acid, molecular formula is C11H9NO4

Adenosine induces bronchial hyperresponsiveness and inflammation in asthmatics through activation of A2B adenosine receptor (A2BAdoR). Selective antagonists have been shown to attenuate airway reactivity and improve inflammatory conditions in pre-clinical studies. Hence, the identification of novel, potent and selective A2BAdoR antagonist may be beneficial for the potential treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Towards this effort, we explored several prop-2-ynylated C8-aryl or heteroaryl substitutions on xanthine chemotype and found that 1-prop-2-ynyl-1H-pyrazol-4-yl moiety was better tolerated at the C8 position. Compound 59, exhibited binding affinity (Ki) of 62 nM but was non-selective for A2BAdoR over other AdoRs. Incorporation of substituted phenyl on the terminal acetylene increased the binding affinity (Ki) significantly to <10 nM. Various substitutions on terminal phenyl group and different alkyl substitutions on N-1 and N-3 were explored to improve the potency, selectivity for A2BAdoR and the solubility. In general, compounds with meta-substituted phenyl provided better selectivity for A2BAdoR compared to that of para-substituted analogs. Substitutions such as basic amines like pyrrolidine, piperidine, piperazine or cycloalkyls with polar group were tried on terminal acetylene, keeping in mind the poor solubility of xanthine analogs in general. However, these substitutions led to a decrease in affinity compared to compound 59. Subsequent SAR optimization resulted in identification of compound 46 with high human A2BAdoR affinity (Ki = 13 nM), selectivity against other AdoR subtypes and with good pharmacokinetic properties. It was found to be a potent functional A2BAdoR antagonist with a Ki of 8 nM in cAMP assay in hA2B-HEK293 cells and an IC50 of 107 nM in IL6 assay in NIH-3T3 cells. Docking study was performed to rationalize the observed affinity data. Structure-activity relationship (SAR) studies also led to identification of compound 36 as a potent A2BAdoR antagonist with Ki of 1.8 nM in cAMP assay and good aqueous solubility of 529 muM at neutral pH. Compound 46 was further tested for in vivo efficacy and found to be efficacious in ovalbumin-induced allergic asthma model in mice. Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Safety of 3-(Benzyloxy)isoxazole-5-carboxylic acid, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 2552-54-7, in my other articles.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Brief introduction of 2552-54-7

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 2552-54-7 is helpful to your research. Related Products of 2552-54-7

Related Products of 2552-54-7, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 2552-54-7, molcular formula is C11H9NO4, introducing its new discovery.

ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11 BETA -HYDROXYSTEROID DEHYDROGENASE TYPE I

Disclosed is a compound useful as an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is a group of the formula: -C(=O)NR4R5, (wherein R4 and R5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: -NR6C(=O)R7, (wherein R6 and R7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently -0- or the like, Z is a bond or the like, R2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R3 is optionally substituted alkyl, optionally substituted alkenyl or the like.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Archives for Chemistry Experiments of 2552-54-7

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. 2552-54-7, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 2552-54-7, name is 3-(Benzyloxy)isoxazole-5-carboxylic acid. In an article£¬Which mentioned a new discovery about 2552-54-7

Process Research and Development of an Enantiomerically Enriched Allyic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines

A robust, cost-effective, and high yielding manufacturing process for enantiomerically enriched (S)-allylic amine 3, a key intermediate for fully synthetic tetracyclines have been developed. Two novel and scalable asymmetric vinylations resulting in high-to-excellent stereoselectivity have been developed for the key step. The final product is purified by an efficient crystallization of a l-tartaric salt. The process described has been used to manufacture ?350 kg of the tartaric salt of 3 with 99.0% ee in 8 steps (35% overall yield) from cheap and readily available dimethyl maleate.

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

New learning discoveries about 2552-54-7

As the paragraph descriping shows that 2552-54-7 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2552-54-7,3-(Benzyloxy)isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

A solution of Example 87D (0.1 g, 0.252 mmol), N-ethyl-N-isopropylpropan-2-amine (0.220 ml, 1.262 mmol) and 3-(benzyloxy)isoxazole-5-carboxylic acid (0.066 g, 0.303 mmol) in N,N- dimethylformamide (1.941 ml) was treated with l-[bis(dimethylamino)methylene]-lH- 1,2,3 – triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.099 g, 0.260 mmol) and the reaction mixture was stirred at room temperature for 20 hours. The reaction mixture was poured into 12 mL water and the resulting suspension was filtered. The solid was washed with water and dried under vacuum. Purification by flash chromatography on silica gel (AnaLogix IntelliFlash 280 system) eluting with a gradient of from 0% to 4% methanol in dichloromethane afforded the title compound. lH NMR (400 MHz, DMSO-d6) delta ppm 2.58 – 2.69 (m, 2H), 3.72 (s, 3H), 3.74 – 3.86 (m, 2H), 4.26 – 4.35 (m, 2H), 5.31 (s, 2H), 6.27 (d, J = 1.6 Hz, 1H), 6.41 – 6.54 (m, 1H), 6.69 (s, 1H), 7.02 (d, J = 5.0 Hz, 1H), 7.1 1 – 7.28 (m, 3H), 7.29 – 7.54 (m, 5H), 8.20 (d, J = 4.9 Hz, 1H), 1 1.57 (brs, 1H). MS (ESI+) m/z 525.1 (M+H)+, 2552-54-7

As the paragraph descriping shows that 2552-54-7 is playing an increasingly important role.

Reference£º
Patent; ABBVIE INC.; ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD.; TONG, Yunsong; BRUNCKO, Milan; CLARK, Richard F.; CURTIN, Michael L.; FLORJANCIC, Alan S.; FREY, Robin R.; GONG, Jianchun; HANSEN, Todd M.; JI, Zhiqin; LAI, Chunqiu; MASTRACCHIO, Anthony; MICHAELIDES, Michael; MIYASHIRO, Juliem; RISI, Roberto M.; SONG, Xiaohong; TAO, Zhi-fu; WOODS, Keith W.; ZHU, Guidong; PENNING, Thomas; SOUERS, Andrew; GOSWAMI, Rajeev; IQUTURI, Omprakash Reddy; DABBEERU, Madhu Babu; WO2014/139328; (2014); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

Analyzing the synthesis route of 2552-54-7

2552-54-7, The synthetic route of 2552-54-7 has been constantly updated, and we look forward to future research findings.

a) Synthesis of (3-benzyloxy-isoxazol-5-yl)-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-methanone To 10 ml of anhydrous tetrahydrofuran, 3-benzyloxy-isoxazol-5-carboxylic acid (50 mg, 0.23 mmol) and a catalytic amount of N,N-dimethyl formamide were added and dissolved, and then oxalyl chloride (35 mg, 0.28 mmol) was slowly added thereto and then stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane, triethylamine (115 mg, 1.15 mmol) and 3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (31 mg, 0.23 mmol) were added thereto and then stirred at room temperature for 2 hours. After completion of the reaction by adding water dropwise, the reaction mixture was extracted with dichloromethane, and the combined organic layer was dried over anhydrous sodium sulfate (Na2SO4), filtered and evaporated under reduced pressure. The residue was purified by column chromatography on amine silica eluding with a solvent of dichloromethane_methanol=30:1. The fractions containing the product were collected and evaporated to obtain (3-benzyloxy-isoxazol-5-yl)-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-methanone as pale-brown liquid (55 mg, 54% in two steps). 1H-NMR (CDCl3, 300 MHz); delta=8.23 (d, 1H, J=5.3 Hz), 7.32-7.48 (m, 6H), 6.87 (d, 1H, J=5.3 Hz), 6.52 (br s, 1H), 5.30 (s, 2H), 4.44 (m, 2H), 4.13 (m, 2H). MS (ESI); 338.1 (M++1).

2552-54-7, The synthetic route of 2552-54-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Ahn, Sung Oh; Park, Chan Hee; Im, Jun Hwan; Lee, Soon Ok; Lee, Kyoung June; Cho, Seong Wook; Ko, Kwang Seok; Han, Sun Young; Lee, Won Il; US2011/28467; (2011); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem